AKT1 and prolymphocytic leukemia: Herling et al. investigated TCR-dependent PI3K/AKT activation and demonstrated that pharmacologic PI3K/AKT inhibitors reduced growth of T-PLL cells [35], whereas only a subset of T-PLL patients responded to PI3K/AKT inhibition in another study [47].